Major histocompatibility complex (MHC) class II molecules are key players in the adaptive immune response. Their role is to sample peptides derived from the breakdown of proteins present in the endosomal compartments of specialized antigen-presenting cells. After stably binding peptide, these molecules move to the cell surface to display their cargo for recognition by CD4 + helper T cells. In this way, helper T cells constantly monitor the contents of the endosomal compartments of antigen-presenting cells. The endosomes and lysosomes are good compartments to sample because they are enriched for proteins that are selectively internalized by antigen-presenting cells, which have evolved mechanisms for uptake of components of microbial pathogens. For example, B cells efficiently internalize antigens through clonally distributed membrane immunoglobulin receptors. The peptides displayed by the MHC class II molecules on the surface of B cells are enriched in those derived from these selectively internalized proteins. This process provides a mechanism for T cells to recognize and interact with B cells that have the same antigen specificity.
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This endosomal sampling mechanism presents a particular problem because MHC molecules are inherently unstable without bound peptide antigen. Once bound, the peptide is situated deep in the peptide-binding site of the MHC molecule, providing interactions essential for stabilizing the correctly folded molecule. As membrane proteins, the α and β subunits of MHC class II molecules initially assemble in the endoplasmic reticulum and the heterodimers must be stabilized before they can be exported from this compartment and routed through the Golgi complex to endosomal vesicles. A specialized membranebound chaperone protein, the MHC class II-associated invariant chain, stabilizes the αβ heterodimer. A segment of the invariant chain appears to interact directly with the peptide-binding site, thereby providing a surrogate peptide to stabilize the assembly of the class II molecule. After transport to endosomal compartments, the invariant chain is rapidly degraded by proteases leaving only a short fragment that is protected from proteases because it is buried in the peptide-binding site. This fragment, termed CLIP (class II-associated invariant chain peptide), must be released, however, so that the class II molecules can bind locally generated peptides and sample the endosomal environment.
Remarkably, a wayward member of the MHC class II family is involved in the displacement of CLIP from the peptide-binding site. HLA-DM is a membrane-bound heterodimer encoded by adjacent genes in the class II region of the MHC gene cluster. The amino acid sequences of the α and β subunits share approximately only 25% similarity to the corresponding subunits of other MHC class II proteins such as HLA-DR, but the domain organization and general conformation of HLA-DM are likely to be very similar to other MHC class II proteins. In contrast with HLA-DR, HLA-DP, and HLA-DQ, HLA-DM has relatively little polymorphism and does not bind peptide antigens. Additional cysteine residues in the membrane-distal domains might create disulfide bonds that preclude the formation of a functional peptidebinding site.
HLA-DM is selectively targeted to endosomal compartments where it directly catalyzes the release of CLIP from class II MHC molecules, freeing the peptide-binding sites to bind 'authentic' peptide antigens [1] [2] [3] [4] . HLA-DM interacts directly with MHC class II proteins, apparently inducing or stabilizing a transient conformational state that favors peptide dissociation [5] . HLA-DM can enhance the release of any peptide but the HLA-DM-catalyzed dissociation rate is directly proportional to the intrinsic rate of peptide dissociation that is observed in the absence of HLA-DM. Thus, if peptides are released very slowly from class II molecules, they dissociate slowly even in the presence of HLA-DM. CLIP is rapidly released in the presence of HLA-DM because its intrinsic rate of dissociation is relatively rapid, but not fast enough to be released without the help of HLA-DM under physiological conditions. The broad specificity of HLA-DM suggests that it might be able to catalyze multiple rounds of peptide exchange in which subpopulations of lower affinity peptides are successively replaced by higher affinity peptides before the final population of MHC class II-peptide complexes are transported out of HLA-DM-containing compartments on their way to the cell surface. It is striking that the basic structure of the MHC class II molecule, which has evolved to bind and display peptide antigens, has been usurped in HLA-DM to play a very different role -the catalysis of peptide exchange in sister molecules.
Several recent studies have indicated that the capacity of class II histocompatibility molecules to have unexpected functions does not end with HLA-DM [6] [7] [8] . The function of HLA-DO, a heterodimeric protein encoded by the HLA-DNA and HLA-DOB genes in the class II region of the MHC gene complex, has long remained elusive. This protein has a high degree of similarity to HLA-DR, HLA-DP, and HLA-DQ but differs from these proteins in its limited polymorphism. Early studies by Lars Karlsson and colleagues [9, 10] demonstrated that the murine homologue of HLA-DO (H-2O) is expressed at low levels as a heterodimer with limited tissue distribution, predominantly in B cells and thymic medullary epithelium. The high degree of evolutionary conservation of HLA-DO suggests it has an important function. This molecule is not expressed at the cell surface and therefore it is unlikely to serve as a specialized antigen-presentation molecule. An important advance was made in 1996 by Karlsson and colleagues [6] , who demonstrated that HLA-DO forms stable complexes with HLA-DM in B cells. Surprisingly, association with HLA-DM was found to be required for HLA-DO to exit the endoplasmic reticulum. HLA-DO then 'hitches a ride' with HLA-DM to lysosome-related MHC class II compartments (MIICs) where most peptide loading occurs. It appears that HLA-DO remains largely or completely associated with HLA-DM in these compartments. The stoichiometry of this association is unclear and might vary depending on cell type or state of activation. These results suggest that HLA-DO might have some role in regulating HLA-DM-catalyzed peptide loading in B cells.
Two recent studies have demonstrated that HLA-DO inhibits HLA-DM activity [7, 8] . In both studies, HLA-DM-catalyzed peptide loading was shown to be inhibited in cells expressing exogenous HLA-DO. Overexpression of HLA-DO results in a phenotype similar to HLA-DMdeficient cells in that most of the MHC class II molecules expressed at the cell surface contain CLIPs rather than the heterogeneous population of peptides that is observed in normal cells. HLA-DO expression does not affect the steady-state expression level or the intracellular distribution of HLA-DM and the HLA-DO protein does not detectably associate with other class II molecules. Studies by van Ham et al. [8] revealed that, compared with lysates from cells expressing HLA-DM alone, detergent lysates of cells expressing both HLA-DM and HLA-DO were markedly deficient in catalyzing peptide release or peptide exchange in experiments with purified HLA-DR molecules. Importantly, similar results were observed in studies of lysates from purified MIIC vesicles. Thus, HLA-DO continues to inhibit HLA-DM function after delivery to endosomal compartments. The conclusion that HLA-DO directly inhibits HLA-DM activity is supported by the experiments of Denzin et al. [7] , who showed that purified HLA-DM-HLA-DO complexes have little or no catalytic activity in peptide-exchange reactions.
Why is an inhibitor of antigen processing expressed in B cells? Given the unique role of the B cell in presenting antigens that have been internalized through surface immunoglobulin, it is appealing to consider the possibility that triggering the B-cell receptor might induce signals that release HLA-DO from HLA-DM, through selective proteolysis or some other mechanism [7, 8] (Figure 1) . Transcription of the HLA-DO and HLA-DM genes is differentially regulated: HLA-DO is not induced by the class II transactivator, CIITA, which induces the expression of HLA-DM, other class II molecules and the invariant chain. It is possible that the ratio of HLA-DM to HLA-DO is increased in B cells activated under certain conditions in which the upregulation of antigen-processing activity is important. At present, however, little is known about the effect of different activation signals on net HLA-DM activity in B cells, and there is no direct evidence that cross-linking the B-cell receptor modulates the inhibitor activity of HLA-DO.
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Figure 1
HLA-DO inhibitory activity might be regulated in endosomal compartments. Functional HLA-DM could be dissociated from HLA-DM-HLA-DO complexes by proteolytic cleavage of HLA-DO or other mechanisms. HLA-DM would then be able to catalyze the replacement of CLIP with other peptides on HLA-DR molecules. The release of HLA-DO from HLA-DM would provide a mechanism to upregulate HLA-DM activity rapidly or to limit peptide loading to a specific subset of endosomal compartments. Their studies with recombinant HLA-DM and HLA-DO proteins provide a potential mechanism. As reported by Denzin et al. [7] and van Ham et al. [8] , HLA-DM-HLA-DO complexes were observed to have no catalytic activity under most conditions. HLA-DM activity was observed, however, under pH conditions similar to those of the most acidic compartments in the endosomal pathway (L. Karlsson, personal communication) . In the presence of HLA-DO, peptide loading might be limited to these acidic compartments, which are probably enriched for antigens internalized through the B-cell receptor.
The observation that HLA-DO is selectively expressed in B cells and thymic medullary epithelial cells raises the interesting possibility that this molecule might play a role in tolerance induction. It has been demonstrated that resting B cells can induce peripheral T-cell tolerance [11, 12] . By partially downregulating HLA-DM activity, HLA-DO might allow CLIP to be replaced by a population of peptide antigens while inhibiting subsequent rounds of peptide exchange that would skew the repertoire of presented antigens by favoring only very stable MHC class II-peptide complexes. In this way, HLA-DO may broaden or alter the repertoire of peptides presented to CD4 + T cells (Figure 2) . Katz et al. [13] have clearly demonstrated that HLA-DM overexpression can reduce the expression of a subset of MHC class II-peptide complexes. Most peptides presented by class II molecules are derived from the breakdown of selfexpressed proteins that are represented in endosomal compartments. HLA-DO might serve to expand self-tolerance by altering the repertoire of the 'self' peptides that are presented in a subset of antigen-presenting cells capable of inducing tolerance.
Despite these recent advances, the physiological role(s) of HLA-DO remain uncertain. Although HLA-DM activity in B cells could be controlled at the level of transcription, certain advantages might result from a mechanism using an inhibitor protein to regulate HLA-DM function. In contrast with CIITA, HLA-DO selectively modulates HLA-DM activity without affecting the expression of the invariant chain or other class II molecules such as HLA-DR. Therefore, HLA-DO may provide a mechanism to partially downregulate HLA-DM activity without affecting the level of expression of cell-surface class II molecules. This mode of action would clearly be advantageous if HLA-DO-expressing cells have a role in broadening CD4 + T-cell tolerance, as discussed above. Protein-mediated regulation would also provide the potential for very rapid enhancement of HLA-DM activity if there is a mechanism for inducing the release of HLA-DO. It should also be noted that human dendritic cells cultured with GM-CSF have been reported to express HLA-DO [14] , raising the possibility that HLA-DO may regulate HLA-DM function in this important class of antigen-presenting cell. Clearly, more work must be carried out before we understand fully the physiological role of this hitchhiking inhibitor. 
